Case number 1:24-cv-00050
Novo Nordisk Inc. et al v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 11, 2024 | 14 | ORDER granting (129) Motion to Consolidate Cases in case 1:23-cv-00101-CFC; granting (12) Motion to Consolidate Cases in case 1:24-cv-00050-CFC. IT IS HEREBY ORDERED that that these actions are consolidated for all purposes, and all papers shall be filed in C.A. No. 23-101-CFC. IT IS FURTHER ORDERED that the Protective Order (C.A. No. 23-101-CFC, D.I. 40) and ESI Order (C.A. No. 23-101- CFC, D.I. 43) shall govern. The Scheduling Order (C.A. No. 23-101-CFC, D.I. 27) shall be modified by the Proposed Consolidated Case Schedule and shall govern. Signed by Judge Colm F. Connolly on 4/10/2024. Associated Cases: 1:23-cv-00101-CFC, 1:24-cv-00050-CFC(nmf) (Entered: 04/11/2024) (2) |
| Apr 11, 2024 | N/A | Case associated with lead case: Create association to 1:23-cv-00101-CFC. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 23-101-CFC ONLY. (nmf) (Entered: 04/11/2024) (0) |
| Apr 4, 2024 | 13 | NOTICE OF SERVICE of Novo Nordisk's Preliminary Disclosure of Asserted Claims Regarding U.S. Patent No. 11,752,198 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 04/04/2024) (5) |
| Mar 28, 2024 | 11 | Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding motion to consolidate. (Egan, Brian) (Entered: 03/28/2024) (1) |
| Mar 28, 2024 | 12 | Joint MOTION to Consolidate Cases - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A)(Egan, Brian) (Entered: 03/28/2024) (0) |
| Mar 26, 2024 | 9 | ANSWER to 1 Complaint , COUNTERCLAIM against All Plaintiffs by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/26/2024) (30) |
| Mar 26, 2024 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 03/26/2024) (2) |
| Jan 29, 2024 | 8 | WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Mylan Pharmaceuticals Inc. waiver sent on 1/26/2024, answer due 3/26/2024. (Murray, Travis) (Entered: 01/29/2024) (1) |
| Jan 18, 2024 | 7 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) (Entered: 01/18/2024) (2) |
| Jan 17, 2024 | N/A | Remark: MDL panel has been advised. (jfm) (Entered: 01/17/2024) (0) |
| Jan 17, 2024 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 01/17/2024) (0) |
| Jan 12, 2024 | 1 | COMPLAINT FOR PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc. (Filing fee $ 405, receipt number ADEDC-4314403.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(jfm) (Entered: 01/16/2024) (0) |
| Jan 12, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) (Entered: 01/16/2024) (3) |
| Jan 12, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/02/2023. Date of Expiration of Patent: 08/24/2038.Thirty Month Stay Deadline: 6/17/2025. (jfm) (Entered: 01/16/2024) (1) |
| Jan 12, 2024 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,752,198 B2. (jfm) (Entered: 01/16/2024) (1) |
| Jan 12, 2024 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk Commercial Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo Holdings A/S for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc. (jfm) (Entered: 01/16/2024) (2) |
| Jan 12, 2024 | 6 | Summons Issued as to Mylan Pharmaceuticals Inc. on 1/12/2024. (jfm) (Entered: 01/16/2024) (2) |
